Compare BGSF & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | ICCC |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 55.5M |
| IPO Year | 2013 | 1995 |
| Metric | BGSF | ICCC |
|---|---|---|
| Price | $6.07 | $6.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 24.1K | 11.6K |
| Earning Date | 03-11-2026 | 03-04-2026 |
| Dividend Yield | ★ 32.36% | N/A |
| EPS Growth | ★ 67.37 | 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $272,499,000.00 | $26,493,169.00 |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $30.20 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $2.91 | $4.52 |
| 52 Week High | $8.20 | $7.60 |
| Indicator | BGSF | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 42.41 |
| Support Level | $5.93 | $6.13 |
| Resistance Level | $6.38 | $6.85 |
| Average True Range (ATR) | 0.26 | 0.23 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 39.77 | 20.00 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.